Nuvectis Pharma (NVCT) Change in Accured Expenses (2021 - 2026)

Nuvectis Pharma has disclosed Change in Accured Expenses across 6 years of filings, most recently posting -$79000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$79000.0, down 416.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 41.57% YoY), and the FY2025 annual result was $1.4 million, down 23.15% from the prior year.
• Change in Accured Expenses came in at -$79000.0 for Q1 2026 at Nuvectis Pharma, down from $1.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.9 million in Q4 2025 to a low of -$699000.0 in Q1 2023.
• The 5-year median for Change in Accured Expenses is $80000.0 (2024), against an average of $291235.3.
• Across the five-year window, Change in Accured Expenses surged 2256.52% in 2022 and tumbled 416.0% in 2026, its largest moves.
• Nuvectis Pharma's Change in Accured Expenses stood at -$305000.0 in 2022, then jumped by 184.26% to $257000.0 in 2023, then surged by 593.77% to $1.8 million in 2024, then climbed by 7.07% to $1.9 million in 2025, then sank by 104.14% to -$79000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$79000.0 (Q1 2026), $1.9 million (Q4 2025), and -$83000.0 (Q3 2025), per Business Quant data.